Is the business good?
How good a business is MEDP?
Medpace Holdings, Inc. keeps 21% of every revenue dollar as operating profit, against 7.1% for the median Diagnostics & Research name.
21%
Operating margin · Diagnostics & Research median 7.1% · 12 months to Q2 2026
- Cash conversion
- 1.44×
Cash conversion · 1.39× a year ago · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- −2.0%
Share count, year on year · bought back, each share owns more of the company
- Gross margin
- 29%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 18% |
| FY2021 | 17% |
| FY2022 | 19% |
| FY2023 | 18% |
| FY2024 | 21% |
| FY2025 | 21% |
Details›
- Gross margin12 months to Q2 2026
- 29%
- Operating margin12 months to Q2 2026
- 21%
- Net margin12 months to Q2 2026
- 18%
- Free cash flow margin
- 25%
- Revenue, trailing twelve months
- $2.78B
- Free cash flow, trailing twelve months
- $707M
- Net income, trailing twelve months
- $492M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Diagnostics & Research
Ranks #3 of 29 by Smart Score